Interview, Fireside Chat, Conference Presentation
a16z Podcast | The Science and Business of Innovative Medicines
- Strategic Portfolio Shift (2018 Transaction): Novartis executed approximately $50 billion in transactions to restructure its portfolio, shifting focus from traditional areas to medicines powered by advanced therapy platforms and data science.
- Divestitures: The company exited consumer healthcare and spun off its medical device and contact lens business (Alcon) due to a lack of long-term leadership potential in those sectors.
- Pipeline Management & Exits: Novartis actively exits therapeutic areas where it cannot sustain long-term scale; the company exited its infectious disease R&D effort after significant deliberation, noting that rebuilding such expertise would require over a decade.
- Success Rate Benchmark: Industry-wide clinical success rates remain static at roughly 5% (one out of 20 medicines succeed once entering human trials) despite an explosion in scientific capability over the last 15 years.
- Internal Success Metric: Novartis maintains a slightly higher internal success rate of 8% to 10% compared to the industry average.
- Standard of Care Mandate: To address flat attrition rates and rising costs, Novartis enforces a discipline where projects must promise to redefine the standard of care rather than offer incremental improvements; otherwise, they are terminated.
- Market Access Integration: Reimbursement strategy is now integrated into Phase II clinical development, requiring market access teams to validate value propositions early rather than waiting for launch.
- Generic Business Role: While generics represent a small portion of Novartis's sales value, they account for approximately 80% of its 70 billion annual medicine doses, primarily through the Sandoz unit providing global access.
- Manufacturing Evolution: Novartis is pivoting from high-volume manufacturing of older medicines to building specialized facilities for cell and gene therapies, which involve lower volumes but higher complexity.
- Digital Therapeutics: Novartis has launched digital therapeutics with FDA-approved labels (e.g., the PEAR app for opioid addiction), treating software as a "drug" and exploring potential applications in obesity and fertility.
- Future Modality Forecasting: CEO Vas Narasimhan predicts that xenotransplantation (generating organs in animals) and tissue regeneration (e.g., cartilage) will become therapeutic realities within the next 10–20 years.
- RNA Technology Application: Novartis is utilizing RNA interference (RNAi) to target "undruggable" proteins like Lipoprotein(a), which is a significant residual risk factor for heart disease not addressed by cholesterol management.
- Platform vs. Bespoke Model: The industry is shifting from bespoke drug development to modular platforms where a single infrastructure (e.g., manufacturing for CAR-T or AAV vectors) can support multiple products across different diseases.
- Infrastructure Strategy (Build vs. Buy): Given the nascent stage and critical nature of supply chains, Novartis has invested $15 billion in 2023 alone to own cell and gene therapy infrastructure rather than relying on external partners.
- Acquisition Integration: To mitigate "Not Invented Here" syndrome, acquired novel technology units are initially kept as independent incubators to grow and mature separate from the larger corporate machine.
- AI Implementation Constraints: Data scientists at Novartis spend the majority of time cleaning and harmonizing data sets before algorithmic analysis; clean, linked historical data remains a scarce resource.
- AI Success Areas: Machine learning has proven effective in "vision" problems (digitizing and analyzing pathology images) and operational command centers (predicting clinical trial enrollment and quality issues).
- AI Financial Application: AI models currently outperform human analysts in predicting free cash flow and key product sales due to the elimination of human bias and access to clean long-term data.
- Clinical Trial Innovation Vision: The ideal future trial would utilize integrated health records and distributed ledgers (blockchain) for patient consent to eliminate the need for redundant, separate databases.
- Real-World Evidence (RWE) Stance: While RWE is valuable for post-approval "Phase 4" analysis and understanding broader effects, randomized, blinded trials remain essential for establishing primary efficacy due to statistical complexity.
- Sensor Limitations: Current consumer-grade sensors lack the clinical validation required to replace rigorous endpoints in trials; continuous monitoring is promising but does not yet replace randomization.
- Talent Acquisition Strategy: Novartis is establishing "Biome" centers (e.g., in San Francisco and London) to access distributed data science talent and foster partnerships with startups without forcing talent relocation.
- Startup Collaboration Approach: To reduce the "elephant and mouse" dynamic, Novartis created a dedicated digital organization using agile methodologies (sprints, scrums) to make the company feel smaller and more approachable for entrepreneurs.
- Investment Evaluation Metrics: R&D project approval requires a "triple score" assessment: financial metrics (NPV, ROI), scientific transformative potential (standard of care shift), and strategic fit.
- Cultural Transformation: Novartis has adopted a culture defined as "inspired, curious, and unbossed" to empower knowledge workers to navigate the rapid failure and iteration required by new modalities like cell therapy.
- Global Innovation Hubs: Research remains centralized in three hubs (Cambridge, Basel, Shanghai), while data science and digital operations are increasingly distributed globally to where specific talent exists.
- CEO Leadership Insight: Having served as CEO for one year, Vas Narasimhan notes that leading a 120,000-person global enterprise requires navigating high-ambiguity crisis management, a sharp contrast to the predictable nature of R&D.
- Advice for Future Leaders: Emerging talent is advised to prioritize leadership skills and multidisciplinary exposure (R&D, commercial, marketing) over purely technical expertise.
- Scientific Humility: The industry produces roughly 1,500 new molecular entities since the FDA's inception, highlighting the difficulty of navigating human biology where only a fraction of the genome and proteins are understood.